Bio-Techne Q2 FY2023: organic revenue up 4% to $271.6M; GAAP EPS $0.31 vs $0.49 YoY

BIO-TECHNE Corp

2023-Q2 EPS reported $0.86 revenue$541,236,000

Organic revenue grew 4% to $271.6M; reported revenue up 1%.
GAAP EPS $0.31, down from $0.49; adjusted EPS $0.47, flat YoY (FX headwind $0.02).
ExoDx Prostate test revenue more than doubled YoY; fourth consecutive record quarter.
Board declared $0.08/share quarterly dividend, payable Feb 27 to holders of record Feb 13.
Record GMP protein sales and launch of RNAscope Plus and MauriceFlex instrument.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

BIO-TECHNE Corp reported financial results for the quarter ended December 31, 2022.

Period: the quarter ended December 31, 2022
Result: reported results

Exact text from the filing

A copy of the press release issued by Bio-Techne Corporation on February 2, 2023, describing the results of operations for the quarter ended December 31, 2022, and its financial condition as of December 31, 2022 is attached hereto as Exhibit 99.1.

View on SEC.gov

Browse all earnings releases →

BIO-TECHNE Corp filing history →

Source: SEC EDGAR

accession 0001558370-23-000758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.